𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?

✍ Scribed by Nabil Ismaili; Sanaa Elmajjaoui; Youssef Bensouda; Rhizlane Belbaraka; Halima Abahssain; Wafa Allam; Zouhour Fadoukhair; Mohamed Mesmoudi; Rachid Tanz; Tarik Mahfoud; Abdelhamid Elomrani; Mouna Khouchani; Yassir Sbitti; Noureddine Benjaafar; Hassan Errihani; Ali Tahri

Book ID
107616053
Publisher
PAGEPress Publications
Year
2011
Tongue
English
Weight
175 KB
Volume
5
Category
Article
ISSN
1970-5557

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Conservative treatment in patients with
Conservative treatment in patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin – assessment of response and toxicity.
✍ Jadwiga NOWAK-SADZIKOWSKA; Teresa KOWALSKA; Jerzy JAKUBOWICZ; Teresa SZPYTMA πŸ“‚ Article πŸ“… 2008 πŸ› Wielkopolskie Centrum Onkologii 🌐 Polish βš– 198 KB
Treatment options for muscle-invasive ur
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin : Report of Southwest Oncology Group Trial 8733
✍ Celestia S. Higano; Catherine M. Tangen; Wael A. Sakr; James Faulkner; Saul E. R πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 162 KB

## Abstract ## BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates for cisplatin‐based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients. ## METHODS. Eligible patients had pr